Louisiana

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A Louisiana-licensed clinician reviews it, typically asynchronously by secure message since Louisiana allows async-first care; a video visit is requested only if your history calls for it. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Louisiana address in 2–3 business days — New Orleans and Baton Rouge typically see the fastest turnaround, with rural parishes sometimes taking a day longer.

The process is the same as for semaglutide — complete Pallas's online intake, and a Louisiana-licensed clinician reviews it, typically without a scheduled video visit under Louisiana's async-first telehealth rules. If appropriate, your clinician can prescribe either compounded tirzepatide, prepared per-patient by a US-licensed §503A pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is available to eligible Louisiana residents through licensed telehealth. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a Louisiana-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. It is legal when dispensed by a licensed compounding pharmacy for an individual patient with a documented clinical need — Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies. Pallas serves Louisiana with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes. Louisiana nurse practitioners prescribe under a collaborative practice agreement with a Louisiana physician, plus an individual prescriptive-authority approval issued by the Louisiana State Board of Nursing before any prescribing begins. Semaglutide and tirzepatide are not controlled substances, so Louisiana permits prescribing them through telehealth without an in-person visit. Every Pallas clinician who treats Louisiana patients holds an active Louisiana license.

Several licensed telehealth platforms serve Louisiana residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in Louisiana, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Louisiana residents and is LegitScript Healthcare Merchant Certified.

No — Louisiana allows asynchronous-first care. A Louisiana-licensed provider can review your intake by secure message and prescribe semaglutide without a scheduled video call, provided the standard of care is met. Your provider may request a video visit or additional information only if your history calls for it.

Most Louisiana patients complete online intake in about five minutes, and a Louisiana-licensed clinician typically reviews it within 1–2 business days, since Louisiana allows asynchronous-first care with no mandatory video visit. If semaglutide is clinically appropriate, your prescription goes to a US-licensed pharmacy, which ships to any Louisiana address in 2–3 business days after filling. An incomplete intake, a missing ID or photo, or a clinician requesting a follow-up video visit can add time — there is no guaranteed timeline, since review depends on your individual history.

Yes — telehealth access through Pallas is the same across Louisiana, whether you're in New Orleans, Baton Rouge, Shreveport, Lafayette, Lake Charles, or a smaller community in Acadiana or elsewhere in the state. A Louisiana-licensed clinician reviews every intake the same way regardless of ZIP code, and licensed partner pharmacies ship both compounded medications and FDA-approved brands like Wegovy^® and Zepbound^® to any Louisiana address. Distance from a major metro does not change your eligibility or your care.

Several telehealth providers prescribe tirzepatide to Louisiana residents. Before choosing one, verify that its clinicians hold an active Louisiana medical license, that it works with US-licensed §503A compounding pharmacies (or offers FDA-approved Zepbound^®/Mounjaro^® as the brand-name option), and that it carries LegitScript Healthcare Merchant Certification — checkable in LegitScript's public database. Pallas serves Louisiana residents and is LegitScript Healthcare Merchant Certified.

Louisiana Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Weight-management coverage is limited, and compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid rules do not apply to our prescriptions.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Louisiana address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in New Orleans, Baton Rouge, or a rural Louisiana parish.

Eligibility is always decided by a Louisiana-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Louisiana-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Louisiana-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Louisiana State Board of Medical Examiners reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Louisiana address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Louisiana address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Louisiana address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Louisiana patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Louisiana during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. Louisiana Medicaid (Healthy Louisiana) covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited, and compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in Louisiana, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1069/mo. Two: if a clinician licensed in Louisiana determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Louisiana weighs your history, goals, and budget to recommend a starting point.